The Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer Monoclonal Antibody Drugs

In some breast cancers, HER2 genes are overexpressed, which leads to HER2+ BC. Historically, HER2+BC was associated with a more aggressive disease course, faster growth and higher risk of recurrence compared to HER2BC. Therefore, it used to be a threat to womens health. Currently, diverse treatment methods are developed, including targeted therapy using monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). However, there is insufficient data and research about the efficacy of specific ADC drugs, for example Kadcyla, as well as the detailed side effects of different drugs. More experiments may have to be carried out in order to obtain more data. This article mainly focuses on comparing different treatment approaches for HER2+ BC. The mechanisms of mAb and ADCs and effect of immunotherapy combined with drugs are analyzed. This article provides a reference for further research about the development and history of mAbs and ADCs. As for the future of treatment of HER2+ BC, more experiments have to be carried out in order to demonstrate the efficacy and safety of new ADC drugs.